ALLK - Allakos prices ~$150M underwritten offering
- Biotechnology company Allakos ( NASDAQ: ALLK ) is pricing an underwritten offering of 29.9M shares at $5.02 per share.
- The expected gross proceeds from the offering, estimated to close on or about Sep. 21, will be ~$150M.
- Logos Capital, Alta Partners, Braidwell, BVF Partners, Commodore Capital, Deep Track Capital, Frazier Life Sciences, New Enterprise Associates ( NEA ), RTW Investments, Surveyor Capital, TCGX and Vivo Capital have agreed to purchase shares in the offering.
- Allakos will sell all the shares in the offering.
- The offering is subject to the satisfaction of customary closing conditions.
- ALLK shares were trading -2.62% pre-market.
- Source: Press Release
For further details see:
Allakos prices ~$150M underwritten offering